We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





LumiraDx Demonstrates Fast, High Performance, Portable POC Diagnostic Solution

By LabMedica International staff writers
Posted on 24 May 2023

LumiraDx (London, UK) is presenting its innovative diagnostic solutions at this year's WorldLab-EuroMedLab in Rome, Italy, 21-25 May, including its LumiraDx Platform which is designed to perform multiple tests on one single instrument wherever needed. More...

The LumiraDx Platform is similar to a portable laboratory, compact yet capable of delivering lab-grade results in a variety of care settings, thereby bringing clinical decision-making closer to the patient. This rapid, high-performing, portable point-of-care (POC) diagnostic solution employs active microfluidic technology, providing results for a range of analytes, including NT-proBNP, HbA1c, and CRP, within minutes. The single, portable instrument offers a simple and uniform workflow for all tests and is user-friendly - all that's needed is to follow the on-screen video instructions for high-sensitivity results in minutes.

The LumiraDx Platform serves as a cost-effective replacement for multiple POC systems. Its compact, lightweight design, combined with actively controlled microfluidic test strips and secure connectivity, yields lab-grade results in a matter of minutes. Both the device and test strip employ several analytical electronic quality control measures to ensure the test's integrity and validity, with automated functionality checks and test strip performance controls being conducted throughout the test's operational stages. Regardless of whether healthcare professionals are using direct fingerstick or swab methods, the LumiraDx Platform's 'easy to use' test workflow employs 'easy to retrieve' small sampling directly at the patient's side.

With a pipeline of over 30 assays, LumiraDx's POCT menu is primarily focused on some of the most commonly diagnosed or managed conditions, including coagulation disorders, infectious disease, cardiovascular conditions, and diabetes. By integrating multiple technologies and sample types into one device, the LumiraDx Platform facilitates the continued expansion of a comprehensive test menu for conditions diagnosed and managed in community-based healthcare settings.

Related Links:
LumiraDx 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.